{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Compensated+Cirrhosis&page=2", "query": { "condition": "Compensated Cirrhosis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Compensated+Cirrhosis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T03:19:05.628Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06051617", "title": "Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Seladelpar", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 318, "start_date": "2023-09-07", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051617" }, { "nct_id": "NCT05282121", "title": "A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Diseases", "Hypertension, Portal" ], "interventions": [ { "name": "Avenciguat", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2022-06-28", "completion_date": "2024-06-07", "has_results": true, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 4, "location_summary": "Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Rialto", "state": "California" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05282121" }, { "nct_id": "NCT04971785", "title": "Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "Semaglutide (SEMA)", "type": "DRUG" }, { "name": "Cilofexor (CILO)/Firsocostat (FIR)", "type": "DRUG" }, { "name": "PTM SEMA", "type": "DRUG" }, { "name": "PTM CILO/FIR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 457, "start_date": "2021-08-09", "completion_date": "2024-12-09", "has_results": true, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 175, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Madison", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04971785" }, { "nct_id": "NCT01672879", "title": "Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Fibrosis Due to NASH" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "SIM", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 259, "start_date": "2012-10-29", "completion_date": "2017-01-03", "has_results": true, "last_update_posted_date": "2019-03-27", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Coronado, California • San Diego, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01672879" }, { "nct_id": "NCT06419374", "title": "A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis" ], "interventions": [ { "name": "Pegozafermin", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "89bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 762, "start_date": "2024-05-24", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 135, "location_summary": "Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 112 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06419374" }, { "nct_id": "NCT04950764", "title": "An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Biliary Cholangitis", "Compensated Cirrhosis", "Hepatic Impairment" ], "interventions": [ { "name": "Seladelpar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2021-11-16", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 11, "location_summary": "Chandler, Arizona • Sacramento, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04950764" }, { "nct_id": "NCT06675929", "title": "A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Compensated Liver Cirrhosis", "Metabolic Dysfunction Associated Steatohepatitis (MASH)" ], "interventions": [ { "name": "BI 770371", "type": "DRUG" }, { "name": "Placebo for BI 770371", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2025-01-20", "completion_date": "2026-01-13", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 13, "location_summary": "Chandler, Arizona • Coronado, California • Montclair, California + 8 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Rialto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06675929" }, { "nct_id": "NCT03855956", "title": "Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Early Cirrhosis" ], "interventions": [ { "name": "KB174", "type": "OTHER" }, { "name": "Maltodextrin", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Kaleido Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2019-02-27", "completion_date": "2019-10-01", "has_results": false, "last_update_posted_date": "2020-05-14", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 4, "location_summary": "Hollywood, Florida • Miami, Florida • Winter Park, Florida + 1 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Monroe", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03855956" }, { "nct_id": "NCT05367596", "title": "OPTIMIzing muScle Preservation in paTients wIth Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Compensated Cirrhosis", "Sarcopenia" ], "interventions": [ { "name": "Continuous Energy Restriction (CER)", "type": "BEHAVIORAL" }, { "name": "Alternate Day Modified Fasting (ADMF)", "type": "BEHAVIORAL" }, { "name": "Group Health Education Sessions", "type": "BEHAVIORAL" }, { "name": "Late Evening Snack", "type": "BEHAVIORAL" }, { "name": "Physical activity", "type": "BEHAVIORAL" }, { "name": "Self-monitoring", "type": "BEHAVIORAL" }, { "name": "Remotely Supervised Exercise Sessions", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-06-22", "completion_date": "2022-12-16", "has_results": false, "last_update_posted_date": "2023-02-09", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05367596" }, { "nct_id": "NCT06465186", "title": "A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-alcoholic Fatty Liver Disease", "Nonalcoholic Steatohepatitis", "NAFLD", "Metabolic Dysfunction-associated Steatotic Liver Disease", "Metabolic Dysfunction-associated Steatohepatitis" ], "interventions": [ { "name": "Efinopegdutide", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 80, "start_date": "2024-07-12", "completion_date": "2026-08-06", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-06-11T03:19:05.628Z", "location_count": 33, "location_summary": "Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 27 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06465186" } ] }